Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia / Schizoaffective Disorder Clear all
Completed Phase 1 Interventional Results available

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine Extended Release, Olanzapine Immediate Release
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Los Alamitos, California • Hollywood, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 8, 2026, 1:37 AM EDT
Not yet recruiting Not applicable Interventional

NST-SPARK Open-Label Phase 1 STTR (IGNITE)

NCT07593456
View directory record Official record
Conditions
Schizophrenia / Schizoaffective Disorder
Interventions
NST-SPARK
Device
Lead sponsor
North Shore Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
2
States / cities
Glen Oaks, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 8, 2026, 1:37 AM EDT
Recruiting Not applicable Interventional

Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness

NCT05157620
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Bipolar Disorder 1
Interventions
Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode

NCT02823041
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
Cognitive Training, Aerobic Exercise, Case management and supportive psychotherapy, Individual Placement and Support
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

NCT05660070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
Interventions
mobile Social Interaction Therapy by Exposure (mSITE)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

Efficacy of Pregnenolone in Patients With Schizophrenia

NCT00615511
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
placebo pregnenolone, pregnenolone
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Piscataway, New Jersey • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 8, 2026, 1:37 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Not applicable Interventional

Mobile CBT for Negative Symptoms

NCT03621774
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Mobile-assisted CBT-informed Skills Training, Supportive Contact
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 8, 2026, 1:37 AM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Motivational Interviewing to Improve Work Outcomes in Schizophrenia

NCT00261716
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
IPS, IE, VOMI
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

NCT00412373
View directory record Official record
Conditions
Schizoaffective Disorder, Psychotic Disorder
Interventions
Placebo, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Targeting Auditory Hallucinations With Alternating Current Stimulation

NCT03221270
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
tACS treatment week, tACS sham week, Maintenance tACS, Maintenance Sham tACS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 4 Interventional

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

NCT00177580
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Pravastatin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 8, 2026, 1:37 AM EDT
Completed No phase listed Observational

Factors Association With Poor Physical Function in Older Adults With Schizophrenia

NCT01092598
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 8, 2026, 1:37 AM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02055287
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Orange, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCT02634684
View directory record Official record
Conditions
Schizophrenia
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

NCT00178932
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
genetic analysis, genetic assay
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 8, 2026, 1:37 AM EDT
Active, not recruiting Not applicable Interventional

Ketogenic Diet in People With Schizophrenia

NCT05968638
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Regular Diet, Ketogenic Diet
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 8, 2026, 1:37 AM EDT
Not listed Phase 1 Interventional

Families Coping With Mental Illness Program

NCT00435721
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Psychoeducation
Behavioral
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2007 · Synced Oct 8, 2026, 1:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 8, 2026, 1:37 AM EDT